AbbVie Inc. (BIT:1ABBV)

Market Cap	363.14B
Revenue (ttm)	50.83B
Net Income (ttm)	2.00B
Shares Out	n/a
EPS (ttm)	1.13
PE Ratio	181.46
Forward PE	17.27
Dividend	4.27 (2.10%)
Ex-Dividend Date	Oct 14, 2025

Volume	n/a
Average Volume	78
Open	203.50
Previous Close	203.50
Day's Range	203.50 - 203.50
52-Week Range	149.00 - 208.00
Beta	n/a
RSI	59.77
Earnings Date	Oct 31, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD